KAPA news

Kairos Pharma's lead candidate ENV-105 won the Cancer Immunology Solution award for targeting drug resistance. The company announced positive interim efficacy data from its Phase 2 mCRPC trial.

Kairos Pharma reported that Phase 2 data showed ENV-105 plus apalutamide improved progression-free survival. The FDA filing documents a significant clinical advancement in metastatic prostate cancer therapy.

Kairos reported interim Phase 1 data showing zero Grade 3+ toxicity with ENV-105 in osimertinib-resistant lung cancer patients. The clean safety profile strengthens the potential for a breakthrough therapy in a substantial drug resistance market.

Kairos Pharma announced a strategic acquisition of worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for NSCLC and gastric cancers, targeting a $16.2B EGFR-mutant lung cancer market. The company plans Phase 1 initiation and multiple clinical milestones through 2026 while maintaining…